Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia, a Phase II Trial
Phase of Trial: Phase II
Latest Information Update: 01 Oct 2017
Price : $35 *
At a glance
- Drugs Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 03 May 2017 Status changed from active, no longer recruiting to completed.
- 19 Oct 2016 Planned End Date changed from 1 Sep 2016 to 1 Mar 2017.
- 29 Jan 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Dec 2015, as reported by ClinicalTrials.gov record.